ICMR, New Delhi in collaboration with the six study sites/hospitals in India is conducting a randomized, placebo-controlled, double blind trial to evaluate the efficacy of a probiotic blend (Vivomixx Drop) in reducing the incidence of neonatal sepsis in low birth weight (LBW) infants in the 0-2-month period. A total of 6100 LBW neonates will be enrolled, 3050 each in intervention and control arm. As one of the 6 participating sites, we will be conducting a study in Meerut, UP, India. In this study LBW babies in the identified hospitals, meeting the eligibility criteria will be enrolled and randomized to receive either probiotic Vivomixx or a similar looking substance (placebo), once daily for 30 days. Follow up visits will be done daily at home during the first week of life, twice a week during second to fourth week of life, and weekly during the second month. During these visits, field worker will screen the infants for morbidity and refer the sick infants to the study hospital for evaluation by the physician. At the facility/hospital, examination for clinical signs, blood samples from sick infants suspected sepsis for diagnosis of neonatal sepsis will be done.